ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$2.02M, compared with $846K a year earlier. Trailing-twelve-month accounts receivables was -$3.13M. Over 3 fiscal years it compounded at +8.3% a year.

Context

  • Accounts receivables amounted to 0.7% of revenue in FY2025, down 3.1 pp from a year earlier.
  • Accounts receivables grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$2.02M or moves back toward the trailing-twelve-month quarterly average of -$783.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.02M+163.9% QoQ
Last fiscal yearDec 2025
-$268K-77.8% YoY
LTMMar 2026
-$3.13M+159.8% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-338.7%——
1 year-77.8%——
3-year CAGR+8.3%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(268K) USD
Year-over-year change
+77.8%

Accounts Receivables vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +159.8% is the 3rd highest of 8, against a peer median of -46.6%.
  • Accounts receivables amounts to 7.7% of revenue for CLPT, versus a peer median of 0.8%.
CLPT Competitors
Accounts Receivables for CLPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVNSAvanos Medical, Inc.LTM Mar 2026$5.5M USD-46.6%—0.8%
OFIXOrthofix Medical Inc.LTM Mar 2026$5.26M USD+166.0%-38.3%0.6%
SIBNSI-BONE, Inc.LTM Mar 2026$4.72M USD-7.3%-22.4%2.3%
VREXVarex Imaging CorporationLTM Apr 2026$3.7M USD-169.8%—0.4%
CTKBCytek Biosciences, Inc.LTM Mar 2026$3.56M USD+210.9%—1.7%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$3.13M USD+159.8%+8.3%7.7%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$1.97M USD-94.6%—0.8%
LABStandard BioTools Inc.LTM Mar 2026$1.1M USD-82.4%—1.3%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding CLPT) —-46.6%-30.3%0.8%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.41M)(16.43M)(22.09M)(18.91M)(25.54M)
Depreciation & Amortization692K777K1.51M1.9M982K
Deferred Income Tax202K0000
Stock-Based Compensation2.08M4.13M6.08M6.91M8.18M
Change in Working Capital(1.68M)(4.29M)(1.4M)1.4M(9.81M)
Accounts Receivables627K(211K)(1.8M)(1.21M)(268K)
Inventory(1.71M)(4.42M)1.25M743K(103K)
Accounts Payables(762K)1.59M03.11M(7.52M)
Other Working Capital165K(1.25M)(846K)(1.24M)(1.92M)
Other Non-Cash Items425K3.78M2.18M(245K)2.27M
Operating Cash Flow(12.7M)(16.17M)(13.72M)(8.95M)(23.93M)
Capital Expenditures(168K)(253K)(717K)(275K)(522K)
Acquisitions (Net)00001.14M
Purchases of Investments0(21.59M)000
Sales of Investments012M000
Other Investing Activities009.67M00
Investing Cash Flow(168K)(10.74M)8.95M(275K)615K
Debt Repayment000(10M)48.09M
Common Stock Issued46.79M745K016.15M3.95M
Common Stock Repurchased00(210K)00
Dividends Paid00000
Other Financing Activities90K(336K)506K40K(1.86M)
Financing Cash Flow46.88M409K296K6.19M50.18M
Effect of Forex Changes00000
Net Change in Cash34.01M(26.49M)(4.48M)(3.04M)26.87M
Free Cash Flow(12.87M)(16.42M)(14.44M)(9.23M)(24.45M)

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.